Do analysts prefer TSTL or NIOX?

NIOX Group has a consensus price target of GBX 86, indicating a potential upside of 34.06%. Given NIOX Group's stronger consensus rating and higher possible upside, analysts plainly believe NIOX Group is more favorable than Tristel. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Tristel 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 NIOX Group 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 3.00

Which has preferable earnings and valuation, TSTL or NIOX?

NIOX Group has lower revenue, but higher earnings than Tristel. Tristel is trading at a lower price-to-earnings ratio than NIOX Group, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Tristel £51.12M 3.67 £6.54M £16.57 23.54 NIOX Group £47.50M 5.47 £995.88M £1.63 39.36

Is TSTL or NIOX more profitable?

Tristel has a net margin of 15.62% compared to NIOX Group's net margin of 14.74%. Tristel's return on equity of 23.05% beat NIOX Group's return on equity. Company Net Margins Return on Equity Return on Assets Tristel 15.62% 23.05% 9.89% NIOX Group 14.74% 10.01% 3.95%

Do analysts rate EKF or TSTL?

EKF Diagnostics presently has a consensus target price of GBX 35, suggesting a potential upside of 40.45%. Given EKF Diagnostics' stronger consensus rating and higher possible upside, equities research analysts plainly believe EKF Diagnostics is more favorable than Tristel. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score EKF Diagnostics 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 3.00 Tristel 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00

Is EKF or TSTL more profitable?

Tristel has a net margin of 15.62% compared to EKF Diagnostics' net margin of 4.86%. Tristel's return on equity of 23.05% beat EKF Diagnostics' return on equity. Company Net Margins Return on Equity Return on Assets EKF Diagnostics 4.86% 3.58% 5.27% Tristel 15.62% 23.05% 9.89%

Is TSTL or SPEC more profitable?

Tristel has a net margin of 15.62% compared to INSPECS Group's net margin of -0.52%. Tristel's return on equity of 23.05% beat INSPECS Group's return on equity. Company Net Margins Return on Equity Return on Assets Tristel 15.62% 23.05% 9.89% INSPECS Group -0.52% -1.19% 0.45%

Tristel (TSTL) Competitors

GBX 390 -0.84 (-0.22%)

As of 04:18 AM Eastern

Compare

TSTL vs. AMS, NIOX, EKF, SPEC, and CREO

Should you buy Tristel stock or one of its competitors? Tristel's main competitors and comparable companies include Advanced Medical Solutions Group (AMS), NIOX Group (NIOX), EKF Diagnostics (EKF), INSPECS Group (SPEC), and Creo Medical Group (CREO). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "healthcare equipment & supplies" industry.

How does Tristel compare to Advanced Medical Solutions Group?

Advanced Medical Solutions Group (LON:AMS) and Tristel (LON:TSTL) are both small-cap healthcare companies, but which is the better business? We will contrast the two companies based on the strength of their media sentiment, institutional ownership, risk, earnings, profitability, dividends, valuation and analyst recommendations.

Advanced Medical Solutions Group has a beta of 0.753, suggesting that its share price is 25% less volatile than the broader market. Comparatively, Tristel has a beta of 0.352, suggesting that its share price is 65% less volatile than the broader market.

Advanced Medical Solutions Group pays an annual dividend of GBX 2.86 per share and has a dividend yield of 1.0%. Tristel pays an annual dividend of GBX 14.20 per share and has a dividend yield of 3.6%. Advanced Medical Solutions Group pays out 173.3% of its earnings in the form of a dividend, suggesting it may not have sufficient earnings to cover its dividend payment in the future. Tristel pays out 85.7% of its earnings in the form of a dividend, suggesting it may not have sufficient earnings to cover its dividend payment in the future. Tristel is clearly the better dividend stock, given its higher yield and lower payout ratio.

Tristel has a net margin of 15.62% compared to Advanced Medical Solutions Group's net margin of 1.58%. Tristel's return on equity of 23.05% beat Advanced Medical Solutions Group's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Advanced Medical Solutions Group	1.58%	1.44%	2.35%
Tristel	15.62%	23.05%	9.89%

Advanced Medical Solutions Group has higher revenue and earnings than Tristel. Tristel is trading at a lower price-to-earnings ratio than Advanced Medical Solutions Group, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Advanced Medical Solutions Group	£233.63M	2.64	£11.22M	£1.65	171.52
Tristel	£51.12M	3.67	£6.54M	£16.57	23.54

21.5% of Advanced Medical Solutions Group shares are owned by institutional investors. Comparatively, 22.4% of Tristel shares are owned by institutional investors. 4.0% of Advanced Medical Solutions Group shares are owned by company insiders. Comparatively, 21.0% of Tristel shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Advanced Medical Solutions Group presently has a consensus target price of GBX 278.33, indicating a potential downside of 1.65%. Given Advanced Medical Solutions Group's stronger consensus rating and higher probable upside, analysts plainly believe Advanced Medical Solutions Group is more favorable than Tristel.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Advanced Medical Solutions Group	0 Sell rating(s)	2 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.33
Tristel	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00

In the previous week, Advanced Medical Solutions Group had 1 more articles in the media than Tristel. MarketBeat recorded 1 mentions for Advanced Medical Solutions Group and 0 mentions for Tristel. Advanced Medical Solutions Group's average media sentiment score of 0.44 beat Tristel's score of 0.00 indicating that Advanced Medical Solutions Group is being referred to more favorably in the media.

Company	Overall Sentiment
Advanced Medical Solutions Group	Neutral
Tristel	Neutral

Summary

Advanced Medical Solutions Group and Tristel tied by winning 9 of the 18 factors compared between the two stocks.

How does Tristel compare to NIOX Group?

Tristel (LON:TSTL) and NIOX Group (LON:NIOX) are both small-cap healthcare companies, but which is the superior business? We will compare the two businesses based on the strength of their media sentiment, institutional ownership, analyst recommendations, dividends, profitability, valuation, risk and earnings.

In the previous week, NIOX Group had 21 more articles in the media than Tristel. MarketBeat recorded 21 mentions for NIOX Group and 0 mentions for Tristel. Tristel's average media sentiment score of 0.00 beat NIOX Group's score of -0.10 indicating that Tristel is being referred to more favorably in the media.

Company	Overall Sentiment
Tristel	Neutral
NIOX Group	Neutral

22.4% of Tristel shares are owned by institutional investors. Comparatively, 7.6% of NIOX Group shares are owned by institutional investors. 21.0% of Tristel shares are owned by insiders. Comparatively, 5.1% of NIOX Group shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

Tristel has a beta of 0.352, indicating that its share price is 65% less volatile than the broader market. Comparatively, NIOX Group has a beta of 0.92, indicating that its share price is 8% less volatile than the broader market.

Tristel pays an annual dividend of GBX 14.20 per share and has a dividend yield of 3.6%. NIOX Group pays an annual dividend of GBX 1.55 per share and has a dividend yield of 2.4%. Tristel pays out 85.7% of its earnings in the form of a dividend, suggesting it may not have sufficient earnings to cover its dividend payment in the future. NIOX Group pays out 95.1% of its earnings in the form of a dividend, suggesting it may not have sufficient earnings to cover its dividend payment in the future. Tristel is clearly the better dividend stock, given its higher yield and lower payout ratio.

NIOX Group has a consensus price target of GBX 86, indicating a potential upside of 34.06%. Given NIOX Group's stronger consensus rating and higher possible upside, analysts plainly believe NIOX Group is more favorable than Tristel.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Tristel	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00
NIOX Group	0 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	3.00

Tristel has a net margin of 15.62% compared to NIOX Group's net margin of 14.74%. Tristel's return on equity of 23.05% beat NIOX Group's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Tristel	15.62%	23.05%	9.89%
NIOX Group	14.74%	10.01%	3.95%

NIOX Group has lower revenue, but higher earnings than Tristel. Tristel is trading at a lower price-to-earnings ratio than NIOX Group, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Tristel	£51.12M	3.67	£6.54M	£16.57	23.54
NIOX Group	£47.50M	5.47	£995.88M	£1.63	39.36

Summary

Tristel beats NIOX Group on 10 of the 18 factors compared between the two stocks.

How does Tristel compare to EKF Diagnostics?

EKF Diagnostics (LON:EKF) and Tristel (LON:TSTL) are both small-cap healthcare companies, but which is the superior business? We will contrast the two businesses based on the strength of their media sentiment, risk, institutional ownership, valuation, profitability, earnings, analyst recommendations and dividends.

Tristel has a net margin of 15.62% compared to EKF Diagnostics' net margin of 4.86%. Tristel's return on equity of 23.05% beat EKF Diagnostics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
EKF Diagnostics	4.86%	3.58%	5.27%
Tristel	15.62%	23.05%	9.89%

Tristel has lower revenue, but higher earnings than EKF Diagnostics. Tristel is trading at a lower price-to-earnings ratio than EKF Diagnostics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
EKF Diagnostics	£51.35M	2.08	£4.68M	£0.58	42.97
Tristel	£51.12M	3.67	£6.54M	£16.57	23.54

EKF Diagnostics has a beta of 0.514, indicating that its share price is 49% less volatile than the broader market. Comparatively, Tristel has a beta of 0.352, indicating that its share price is 65% less volatile than the broader market.

EKF Diagnostics presently has a consensus target price of GBX 35, suggesting a potential upside of 40.45%. Given EKF Diagnostics' stronger consensus rating and higher possible upside, equities research analysts plainly believe EKF Diagnostics is more favorable than Tristel.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
EKF Diagnostics	0 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	3.00
Tristel	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00

In the previous week, EKF Diagnostics' average media sentiment score of 0.00 equaled Tristel'saverage media sentiment score.

Company	Overall Sentiment
EKF Diagnostics	Neutral
Tristel	Neutral

21.5% of EKF Diagnostics shares are owned by institutional investors. Comparatively, 22.4% of Tristel shares are owned by institutional investors. 40.2% of EKF Diagnostics shares are owned by insiders. Comparatively, 21.0% of Tristel shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

Summary

EKF Diagnostics and Tristel tied by winning 7 of the 14 factors compared between the two stocks.

How does Tristel compare to INSPECS Group?

Tristel (LON:TSTL) and INSPECS Group (LON:SPEC) are both small-cap healthcare companies, but which is the superior stock? We will compare the two companies based on the strength of their valuation, analyst recommendations, media sentiment, earnings, risk, dividends, profitability and institutional ownership.

Tristel has a net margin of 15.62% compared to INSPECS Group's net margin of -0.52%. Tristel's return on equity of 23.05% beat INSPECS Group's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Tristel	15.62%	23.05%	9.89%
INSPECS Group	-0.52%	-1.19%	0.45%

Tristel has higher earnings, but lower revenue than INSPECS Group. INSPECS Group is trading at a lower price-to-earnings ratio than Tristel, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Tristel	£51.12M	3.67	£6.54M	£16.57	23.54
INSPECS Group	£193.23M	0.49	-£4.11M	-£5.34	N/A

Tristel has a beta of 0.352, indicating that its stock price is 65% less volatile than the broader market. Comparatively, INSPECS Group has a beta of 1.603, indicating that its stock price is 60% more volatile than the broader market.

In the previous week, INSPECS Group had 1 more articles in the media than Tristel. MarketBeat recorded 1 mentions for INSPECS Group and 0 mentions for Tristel. INSPECS Group's average media sentiment score of 0.75 beat Tristel's score of 0.00 indicating that INSPECS Group is being referred to more favorably in the news media.

Company	Overall Sentiment
Tristel	Neutral
INSPECS Group	Positive

22.4% of Tristel shares are held by institutional investors. Comparatively, 0.7% of INSPECS Group shares are held by institutional investors. 21.0% of Tristel shares are held by company insiders. Comparatively, 19.6% of INSPECS Group shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Summary

Tristel beats INSPECS Group on 9 of the 13 factors compared between the two stocks.

How does Tristel compare to Creo Medical Group?

Tristel (LON:TSTL) and Creo Medical Group (LON:CREO) are both small-cap healthcare companies, but which is the better investment? We will compare the two companies based on the strength of their valuation, institutional ownership, profitability, earnings, media sentiment, dividends, risk and analyst recommendations.

Tristel has a net margin of 15.62% compared to Creo Medical Group's net margin of -268.57%. Tristel's return on equity of 23.05% beat Creo Medical Group's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Tristel	15.62%	23.05%	9.89%
Creo Medical Group	-268.57%	-38.29%	-20.09%

Tristel has higher revenue and earnings than Creo Medical Group. Creo Medical Group is trading at a lower price-to-earnings ratio than Tristel, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Tristel	£51.12M	3.67	£6.54M	£16.57	23.54
Creo Medical Group	£7M	6.90	-£25.04M	-£5.00	N/A

Tristel has a beta of 0.352, meaning that its share price is 65% less volatile than the broader market. Comparatively, Creo Medical Group has a beta of 1.563854, meaning that its share price is 56% more volatile than the broader market.

In the previous week, Tristel's average media sentiment score of 0.00 equaled Creo Medical Group'saverage media sentiment score.

Company	Overall Sentiment
Tristel	Neutral
Creo Medical Group	Neutral

22.4% of Tristel shares are owned by institutional investors. Comparatively, 44.0% of Creo Medical Group shares are owned by institutional investors. 21.0% of Tristel shares are owned by insiders. Comparatively, 7.6% of Creo Medical Group shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Summary

Tristel beats Creo Medical Group on 8 of the 11 factors compared between the two stocks.

Get Tristel News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

Media Sentiment Over Time

This chart shows the average media sentiment of LON and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

TSTL vs. The Competition

Export

Metric	Tristel	Healthcare Equipment & Supplies Industry	Healthcare Sector	LON Exchange
Market Cap	£187.49M	£6.16B	£7.79B	£2.80B
Dividend Yield	3.77%	1.68%	2.47%	5.09%
P/E Ratio	23.54	37.78	34.55	23.19
Price / Sales	3.67	5.33	8.91	5.04
Price / Cash	20.96	23.49	21.62	20.23
Price / Book	5.71	5.12	4.89	2.49
Net Income	£6.54M	£144.99M	£3.51B	£5.88B
7 Day Performance	-4.04%	-0.32%	-0.18%	-0.94%
1 Month Performance	-9.83%	-1.94%	-5.28%	-1.66%
1 Year Performance	5.41%	3.31%	2.68%	7.16%

Tristel Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
TSTL Tristel	N/A	GBX 390 -0.2%	N/A	+5.6%	£187.49M	£51.12M	23.54	208
AMS Advanced Medical Solutions Group	0.3882 of 5 stars	GBX 282.52 -0.2%	GBX 278.33 -1.5%	+33.9%	£615.06M	£233.63M	171.22	10
NIOX NIOX Group	1.8906 of 5 stars	GBX 63.70 +2.1%	GBX 86 +35.0%	-4.5%	£268.09M	£47.50M	39.08	92	Gap Up
EKF EKF Diagnostics	N/A	GBX 25.50 +0.8%	GBX 35 +37.3%	-2.8%	£109.13M	£51.35M	43.97	356	Gap Down
SPEC INSPECS Group	N/A	GBX 87 -3.3%	N/A	+24.3%	£94.98M	£193.23M	N/A	1,673

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (LON:TSTL) was last updated on 11/9/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Tristel (TSTL) Competitors

TSTL vs. AMS, NIOX, EKF, SPEC, and CREO

How does Tristel compare to Advanced Medical Solutions Group?

Summary

How does Tristel compare to NIOX Group?

Summary

How does Tristel compare to EKF Diagnostics?

Summary

How does Tristel compare to INSPECS Group?

Summary

How does Tristel compare to Creo Medical Group?

Summary

Media Sentiment Over Time

TSTL vs. The Competition

Tristel Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Tristel (TSTL) Competitors

TSTL vs. AMS, NIOX, EKF, SPEC, and CREO

How does Tristel compare to Advanced Medical Solutions Group?

Which has more risk and volatility, AMS or TSTL?

Is AMS or TSTL a better dividend stock?

Is AMS or TSTL more profitable?

Which has higher earnings and valuation, AMS or TSTL?

Do insiders and institutionals hold more shares of AMS or TSTL?

Do analysts rate AMS or TSTL?

Does the media prefer AMS or TSTL?

Summary

How does Tristel compare to NIOX Group?

Does the media refer more to TSTL or NIOX?

Do institutionals & insiders believe in TSTL or NIOX?

Which has more volatility & risk, TSTL or NIOX?

Is TSTL or NIOX a better dividend stock?

Do analysts prefer TSTL or NIOX?

Is TSTL or NIOX more profitable?

Which has preferable earnings and valuation, TSTL or NIOX?

Summary

How does Tristel compare to EKF Diagnostics?

Is EKF or TSTL more profitable?

Which has stronger earnings & valuation, EKF or TSTL?

Which has more volatility and risk, EKF or TSTL?

Do analysts rate EKF or TSTL?

Does the media favor EKF or TSTL?

Do institutionals & insiders have more ownership in EKF or TSTL?

Summary

How does Tristel compare to INSPECS Group?

Is TSTL or SPEC more profitable?

Which has better valuation & earnings, TSTL or SPEC?

Which has more volatility & risk, TSTL or SPEC?

Does the media prefer TSTL or SPEC?

Do insiders & institutionals believe in TSTL or SPEC?

Summary

How does Tristel compare to Creo Medical Group?

Is TSTL or CREO more profitable?

Which has preferable earnings & valuation, TSTL or CREO?

Which has more volatility & risk, TSTL or CREO?

Does the media refer more to TSTL or CREO?

Do institutionals and insiders hold more shares of TSTL or CREO?

Summary

Media Sentiment Over Time

TSTL vs. The Competition

Tristel Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools